Redx Pharma plc Redx to host Virtual R&D Day on 11 October 2021 (0311O)
05 Octubre 2021 - 1:00AM
UK Regulatory
TIDMREDX
RNS Number : 0311O
Redx Pharma plc
05 October 2021
REDX PHARMA PLC
("Redx" or the "Company")
Redx to host Virtual R&D Day on 11 October 2021
Alderley Park, UK, 5 October 2021 - Redx Pharma (AIM: REDX), the
drug discovery and development company focused on cancer and
fibrosis, will host a Virtual R&D Day on 11 October 2021 at
1:00pm BST (8:00am EDT).
The R&D Day will include an update from the Company's
leadership team on Redx's RXC004 programme and the potential of
porcupine inhibition in Wnt-ligand driven colorectal, pancreatic
and biliary cancers. There will also be an update on the Phase 1
study of RXC007, the Company's selective ROCK2 inhibitor , being
developed for idiopathic pulmonary fibrosis.
The programme includes presentations from leading experts:
-- Professor Scott Kopetz, Department of Gastrointestinal
Medical Oncology, Division of Cancer Medicine, The University of
Texas MD Anderson Cancer Center
Presentation Title: 'Potential of Porcupine Inhibition with
RXC004 in Genetically Selected Patients with Metastatic MSS
Colorectal Cancer'
-- Professor Toby Maher, Professor of Medicine and Director of
Interstitial Lung Disease, Keck School of Medicine, University of
Southern California, Los Angeles
Presentation Title: 'Idiopathic Pulmonary Fibrosis'
-- Professor Gisli Jenkins, Faculty of Medicine, National Heart
& Lung Institute, Imperial College London
Presentation Title: 'The Importance of ROCK in Fibrosis'
To register for the webcast, please email
redxpharma@fticonsulting.com. A recording of the webcast will be
available on Redx's website after the event.
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
918
UK Headquarters
Lisa Anson, Chief Executive Officer
Karl Hård, Head of Investor Relations
US Office
Peter Collum, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser) T: +44 203 368
3550
Matt Davis/ Adam Dawes
WG Partners LLP (Joint Broker) T: +44 20 3705
9330
Claes Spång/ David Wilson
Panmure Gordon (UK) Limited (Joint Broker) T: +44 20 7886
2500
Rupert Dearden/ Freddy Crossley/ Emma Earl
FTI Consulting T: +44 20 3727
1000
Simon Conway/ Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is focused on the discovery and
development of novel targeted medicines for the treatment of cancer
and fibrotic diseases, aiming initially to progress them to
clinical proof of concept, before evaluating options for further
development and potential value creation. Redx's lead oncology
asset, the Porcupine inhibitor RXC004, is expected to commence a
Phase 2 programme in H2 2021. The Company's selective ROCK2
inhibitor, RXC007, is in development for idiopathic pulmonary
fibrosis and commenced a Phase 1 clinical study in June 2021 for
which results are expected in 2022.
The Company has a strong track record of discovering new drug
candidates through its core capability of converting medicinal
chemistry insights into differentiated and commercially attractive
drug candidates, with five proprietary or partnered assets in late
pre-clinical or clinical development. One of those assets, a BTK
inhibitor - pirtobrutinib/LOXO-305 - was sold to Loxo Oncology (now
Eli Lilly) and is currently in Phase 3 clinical studies in chronic
lymphocytic leukaemia. In addition, Redx has forged pre-clinical
asset partnerships with other blue chip companies including
AstraZeneca and Jazz Pharmaceuticals.
To subscribe to Email alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDKPBNPBDKKKK
(END) Dow Jones Newswires
October 05, 2021 02:00 ET (06:00 GMT)
Redx Pharma (LSE:REDX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Redx Pharma (LSE:REDX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024